Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06482268 · ClinicalTrials.gov registry record · Phase 1
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
A Phase 1 study of PD - Parkinson's Disease, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT06482268: Recruiting Phase 1 study of PD - Parkinson's Disease, sponsored by University of California, San Diego.
NCT06482268 is a Phase 1 study of PD - Parkinson's Disease that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06482268, a Phase 1 study of PD - Parkinson's Disease, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
Primary Outcome
For adverse events reported, the severity will be assessed, and the incidence in the treatment period will be determined.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
What NCT06482268 shows while recruiting
NCT06482268 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with PD - Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001) is the first listed.
NCT06482268 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06482268 about?
NCT06482268 is a clinical study titled "Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)". To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
What is the current status of trial NCT06482268?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2024-06-01. Estimated completion is 2028-05.
What conditions does trial NCT06482268 study?
This clinical trial studies the following conditions: PD - Parkinson's Disease.
What interventions are being tested in trial NCT06482268?
The interventions under investigation include: Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06482268?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06482268 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06482268's enrollment target sits among peer trials
7 1973rd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI